Dr. Raymond M. Esper, MD

Dr. Esper practices at Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida.

Dr. Esper's NPI, 1407085376, was assigned on July 13, 2009. Dr. Esper graduated from Wayne State University School Of Medicine in 2009. Dr. Esper holds Florida license ME126015.

Dr. Esper's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West, at 1708 Cape Coral W Pkwy, Cape Coral, FL 33914 in Lee County. The practice phone is (239) 541-4633.

Dr. Esper's primary practice is Florida Cancer Specialists & Research Institute - Cape Coral Cay West in Cape Coral, Florida. Dr. Esper is also affiliated with Cape Coral Hospital. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Esper to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Esper practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Esper's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Esper is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Esper's licenses on file in 4 states: Florida, Hawaii, Michigan and California.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Esper treats.

CMS data shows 275,689 Medicare services from Dr. Esper across 66 procedure codes in 2024, for 1,382 Medicare patients. Medicare paid $3,912,735 for them.

CMS counts 1,382 Medicare patients who saw Dr. Esper in 2024. The largest group is 75 to 84, with 618 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Esper's median patient age at 74, with 54% women.

In 2024, Dr. Esper wrote 1,945 Medicare Part D claims for 325 patients. 66% of them were for generic drugs. CMS names the drug for 1,607 of them, across 38 drugs with 11 or more claims each, at $7,968,167 in total drug cost. In 2023, CMS named 1,357 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Esper for performance year 2024, reported as part of a group. Dr. Esper accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Esper, published from 2006 to 2024. 2006 was the busiest year, with 2. The most frequent topics are Cells, Cultured, Chick Embryo and Ganglia, Spinal. Dr. Esper's most frequent co-authors are Bruce Evan Johnson, MD, Daniel Morgensztern, MD and Gregory A. Otterson, MD.

CMS Open Payments shows 1,803 general payments to Dr. Esper from 97 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Merck Sharp & Dohme Corporation paid the most, $3,131. It also lists 5 research payments totaling $8,000 from 2021 to 2024.

Dr. Esper graduated from Wayne State University School Of Medicine in 2009.

Dr. Esper is in network with 20 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.